Rick Simpson Oil (RSO) in Shelby County, Indiana: The Complete Guide by OilWell Cannabis

If you’re reading this in Shelby County—maybe in Shelbyville, or out in the countryside near Morristown, or commuting back from Indianapolis—you’ve probably heard whispers about Rick Simpson Oil. Maybe a neighbor mentioned it at the Friday night football game. Maybe someone in your church group is using it for their cancer treatments. Or maybe you’re up late searching because the pain pills aren’t working and you’re looking for something that makes sense for your life here in the Hoosier heartland.

We get it. Shelby County isn’t like California or Colorado. We’re not surrounded by dispensaries. We’re surrounded by cornfields, family farms, and communities where people still shake hands and look you in the eye. We’re a place where pharmaceutical options are often the first—and sometimes only—thing doctors mention. But those options don’t always work. They come with side effects that can be just as debilitating as the condition itself. And they don’t always fit the values of folks here who prefer natural, plant-based approaches when possible.

That’s why we at OilWell Cannabis, based in Houston, Texas, have made it our mission to get real, research-backed, legally compliant RSO into the hands of people who need it—right here in Shelby County and across Indiana. We don’t have a storefront in Shelbyville. But we can get our product to your doorstep, legally and discreetly, with the full transparency you deserve.

This guide is for you, Shelby County. It’s not a sales pitch. It’s everything we know, everything the science says, and everything you need to make an informed decision about whether RSO might be right for you or someone you love. No snake oil. No hype. Just the facts, grounded in the same straight-talk values that define life in Indiana.

Understanding Rick Simpson Oil: What Shelby County Needs to Know

Who Was Rick Simpson, and Why Does His Story Matter Here?

Rick Simpson wasn’t a doctor. He was a power engineer from Nova Scotia—a working-class guy, not unlike the farmers and factory workers who built Shelby County. In 1997, he fell from scaffolding at a hospital in Moncton and suffered a serious head injury. The medications doctors gave him either didn’t work or made things worse. When he asked his physician about cannabis, the doctor refused to consider it.

Sound familiar? Here in Shelby County, we’ve seen the same pattern. Maybe you’ve had a workplace injury at one of the manufacturing plants. Maybe you’ve been prescribed opioids that left you foggy and dependent. Maybe your doctor at IU Health Methodist or Franciscan Health in Indianapolis dismissed cannabis as an option. Simpson’s story resonates because it’s the same story playing out in rural communities across Indiana—people searching for alternatives when conventional medicine falls short.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH study at the Medical College of Virginia that showed THC could slow tumors in mice. That study was never replicated in humans, but it sparked something in Simpson. In 2003, he claimed that applying cannabis oil to three bumps on his arm—diagnosed as basal cell carcinoma—made them disappear in four days. No biopsy confirmed this. No doctor verified it. But that personal experience became the origin story of RSO.

Important context for Shelby County: Simpson’s account is personal testimony, not medical evidence. But it’s historically significant because it launched a global movement. Here in Indiana, where we’re often skeptical of outsiders telling us what works, Simpson’s story matters because it came from a regular person, not a pharmaceutical company. That authenticity is powerful—but it doesn’t replace clinical proof.

The Traditional RSO Protocol: What Simpson Recommended

Simpson developed a specific 60-gram, 90-day protocol that many people in Shelby County have heard about through online forums or cancer support groups. Here’s what it entailed:

The Goal: Consume 60 grams of concentrated cannabis oil over approximately 90 days.

The Titration Schedule:

• Week 1: Start with a dose the size of half a grain of rice (about 10-15 mg) taken three times daily. Total daily intake: 30-45 mg.
• Weeks 2-5: Double the dose every four days until reaching about 1 gram (1,000 mg) per day, divided into three doses.
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed.

Administration Methods:

• Oral/Sublingual: Primary method for internal cancers and systemic conditions.
• Topical: For skin cancers, applied directly to lesions with bandages changed every 3-4 days.
• Not Recommended as Primary: Inhalation (smoking/vaping) for immediate symptom relief only.

Tolerance and Psychoactive Effects: Simpson claimed patients develop tolerance to THC’s psychoactive effects within 3-4 weeks. He recommended nighttime dosing initially and warned against driving during titration.

Post-Protocol Maintenance: After completing the 60 grams, Simpson recommended 1-2 grams per month indefinitely.

Dietary Recommendations: Reduce sugar, avoid processed foods—general wellness advice, not a systematic protocol.

Critical Context for Shelby County:

• This protocol was never validated in controlled clinical trials.
• Traditional RSO was crude, unstandardized, and variable in potency.
• Peak dosing delivers 600-900 mg of delta-9 THC daily—doses far exceeding anything studied clinically.
• At those levels, risks include severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• For cancer patients in Shelby County—perhaps receiving treatment at IU Health Simon Cancer Center or Community Hospital South—using unregulated oil as a primary treatment could delay proven therapies and cause real harm.

What Traditional RSO Actually Was

Understanding what Simpson made helps Shelby County residents evaluate what’s being sold today.

Source Material: Single high-THC indica strain, no standardization. If you’re buying from someone locally, you have no idea what strain they used or how it was grown.

Extraction Solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other carcinogens.

Extraction Process: Basically a bucket, solvent, filter, and rice cooker. The heat evaporated the solvent but also destroyed terpenes and fully decarboxylated THCa into THC.

Appearance: Nearly black, thick, tar-like oil with possible solvent-residual smell.

Cannabinoid Profile: 60-90% delta-9 THC, minor cannabinoids at natural ratios, unmeasured and unverified.

Terpene Content: Essentially none—destroyed by heat and solvent.

Standardization: Zero. Every batch was different. No lab testing, no Certificate of Analysis (COA).

Residual Solvent Risk: Incomplete solvent purging leaves toxic residues. Without lab testing, you can’t verify safety.

Bottom Line for Shelby County: If someone in your community is making “RSO” in their garage using Simpson’s method, you’re getting a crude, potentially unsafe product with unknown potency and no quality control. That’s not medicine—that’s gambling with your health.

Simpson’s Claims vs. The Evidence: What Shelby County Should Know

Simpson claimed RSO could cure cancer and treat dozens of conditions. Let’s look at what the evidence actually shows:

What Simpson Was Not:

• Not a scientist, physician, or researcher
• Never conducted or published a clinical trial
• Never submitted his claims to peer review
• His evidence was personal experience and testimonials only

What Preclinical Literature Shows:

• In vitro studies show THC and CBD can induce apoptosis (cell death) and inhibit tumor growth in cell lines .
• Animal studies show some tumor inhibition in mice and rats .
• These findings are scientifically interesting but haven’t translated to human cancer cures.

What Preclinical Literature Does NOT Show:

• No human clinical trial has demonstrated RSO cures cancer.
• The gap between animal results and human outcomes is vast—this is true across all oncology research.
• Small human trials in glioblastoma have been exploratory, not conclusive .

Institutional Positions:

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research but does not endorse cannabis as cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) have specific approvals for other conditions [1].
• Health Canada: Never approved RSO for cancer.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure [1].

What Simpson Got Right:

• He drew attention to cannabinoids as serious medicine when the world ignored them.
• He helped create the conditions for today’s legal cannabis industry.
• The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated:

• Cancer cure claims exceed the evidence.
• Encouraging patients to use RSO instead of proven cancer therapies can cause real harm through delayed treatment.
• For Shelby County residents facing cancer diagnoses, RSO should be considered a complementary option to discuss with your oncologist—not a replacement for surgery, radiation, or chemotherapy.

The Evolution of RSO: From Simpson’s Kitchen to Modern Science

Today, “RSO” is used loosely. Many products labeled RSO bear little resemblance to Simpson’s original. Some are just THC distillate in a syringe. Others are CBD oil with a fancy label. This creates confusion for Shelby County buyers who deserve to know what they’re getting.

Simpson himself was critical of commercial products, believing they betrayed his free-access philosophy. He gave his oil away; companies sell it. But modern RSO has evolved for good reasons:

• Safety: Food-grade ethanol or CO₂ extraction eliminates toxic solvent residues.
• Standardization: Lab testing ensures consistent potency and purity.
• Precision: Known cannabinoid ratios allow accurate dosing.
• Terpene Preservation: Modern methods preserve or reintroduce beneficial terpenes.
• Patient Control: THCa can be kept raw or activated at home.

The question isn’t whether to honor Simpson’s vision—it’s how to make it safer, more effective, and legally accessible for people in Shelby County who need it.

OilWell Cannabis: Our Story, Your Access

Who We Are: From McAllen to Shelby County

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But our roots trace back to McAllen, Texas—right across the river from Reynosa, Mexico. The McAllen-Reynosa Borderplex is one of the most economically challenged and dangerous regions along the border. Colin grew up seeing violence, watching friends killed or imprisoned, and learning to hustle in an environment where survival meant taking risks.

By sixteen, he had to leave home. He chose cannabis over darker paths—seeing it as safer and more beneficial than the alternatives. He learned the plant intimately in the traditional, pre-legalization world, then transitioned to legal business as laws changed.

Colin later became a software engineer, doing custom development for Baylor College of Medicine in the Texas Medical Center. That combination—deep plant knowledge plus medical-grade technical precision—is what defines OilWell’s approach today.

Bentley: The Dog Who Started Everything

Our company’s origin story begins with Bentley—a dog who was more than a pet, he was family. When Bentley fell seriously ill, veterinarians recommended euthanasia. He was paralyzed in his back legs. Pain meds would destroy his organs. The choice was prolonged suffering or mercy killing.

Colin refused to give up. Through a rescue worker named Jessica, he discovered CBD. He created a CBD golden paste formula. Bentley got up, walked over, and brought his ball to play. From paralyzed to playing fetch. Dogs don’t respond to placebo—that was real medicine.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed formulas for every age-related condition:

• Neurodegeneration: Led to CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection.
• Dementia: Led to CBC’s role in neurogenesis.
• Glaucoma: Led to THC’s CB1 agonism for intraocular pressure.
• Arthritis: Led to multi-pathway anti-inflammation using CBD, CBG, THCa, and beta-caryophyllene.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. That precision—Bentley’s life depending on formula accuracy—is the foundation of our RSO formula.

Colin’s Personal Journey: PTSD, Benzos, and Cannabinoids

Colin knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he quit Xanax cold turkey—a notoriously dangerous feat—he used the cannabinoid knowledge he developed for Bentley.

Our Peace Gummies formula was created during midnight experiments while fighting benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This isn’t theoretical knowledge. He lived what many in Shelby County are living: desperation for relief, failed pharmaceuticals, discovering that cannabinoids work when pills don’t.

Doctors Use Our Formulas

Over time, we’ve developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. We’ve created custom products for vegans, diabetics, and those with specific health needs—because Shelby County residents deserve options that fit their lives.

ABC13: Houston’s News, Shelby County’s Validation

Between 2019 and 2023, ABC13 Houston—America’s fourth-largest city’s top news source—featured Colin and OilWell Cannabis in seven comprehensive segments. Five different reporters covered us across business, law, medicine, community health, and politics. No other Houston cannabis operator matches that frequency or breadth.

Our Media Record:

1. September 2019: “Texas CBD businesses booming”—Colin’s foundational quote: “I’m not trying to sell people snake oil… there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of.”
2. March 2021: “Entrepreneur creates direct-to-consumer business”—Highlighted our ecosystem support for other entrepreneurs.
3. May 2021: “What is Delta 8 THC”—Colin’s iconic honesty: “Maybe you want to get high.”
4. August 2021: “Houston CBD shop giving away free products for COVID vaccine”—We donated ~$35,000 in product (1,000 caviar pre-rolls) to encourage vaccination, coordinating with the city of Houston. No political strings.
5. October 2021: “Texas ban over Delta 8″—When Texas reclassified Delta-8 as Schedule I overnight, Colin proactively removed all products and warned other operators who were unknowingly shipping narcotics. We absorbed the revenue loss to act ethically.
6. October 2022: “Biden marijuana pardon”—Revealed Colin’s personal marijuana conviction history. He knows the collateral consequences: housing, loans, banking challenges. “I would love to see people not get hurt for this anymore.”
7. April 2023: “Marijuana industry getting creative”—Colin growing hemp on camera, calling it a “Renaissance.” Compared Texas’s 10,000 active medical marijuana patients to Florida’s 700,000.

The Through-Line: These features aren’t marketing—they’re independently produced editorial content from a major network that repeatedly identified Colin as Houston’s most credible cannabis voice. That recognition can’t be purchased. It can only be earned.

Our Operations: Real Business, Real Quality

Today, OilWell Cannabis operates from Montrose, Houston (810 Richmond Avenue, Houston, TX 77006). We’ve been in business since 2019, generate ~$1M annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston—no mass production, no outsourcing. Colin brings Houston grit and McAllen resilience, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Four Principles

Our RSO is not traditional Rick Simpson Oil. It’s informed by Simpson’s tradition but deliberately different in ways that solve problems for Shelby County residents.

1. Accessibility Over Gatekeeping

No medical card required. Anyone 21+ can purchase. We ship nationwide and internationally to where hemp-derived products are legal.

For Shelby County, this is crucial. Indiana’s medical marijuana program is one of the most restrictive in America—only ~10,000 Texans actively use it compared to Florida’s 700,000 with similar population. Our model bypasses that gatekeeping. You don’t need a qualifying condition. You don’t need a doctor’s permission. You just need to be an adult who wants to explore cannabinoid options.

2. Patient-Controlled Potency

Traditional RSO was always fully psychoactive. Our sublingual formula contains 1,500mg THCa in its raw, non-psychoactive form. You decide:

• Raw (no heat): All 1,500mg stays as THCa—completely non-psychoactive, suitable for daytime use while working, driving, or caring for family.
• Fully Activated (home decarb): Heat at 260°F for 45-60 minutes converts 1,500mg THCa → ~1,315mg delta-9 THC. Combined with existing 90mg delta-9, you get ~1,405mg total—comparable to traditional illegal RSO, 100% legally.
• Partial Activation: Transfer a portion to a separate container, decarb only what you need, preserve the rest raw.

The Science: THCa molecular weight = 358.47 g/mol. Conversion ratio: 1mg THCa = 0.877mg delta-9 THC after decarboxylation (CO₂ loss).

For Shelby County workers—whether you’re at the Honda plant, driving truck, or working in healthcare—this means you can use RSO during the day without impairment, then activate it at night for full-spectrum relief.

3. Open-Source Formulas

We publish our complete formulas publicly—every cannabinoid, every milligram, every percentage. If you can’t afford our products, you can source ingredients and make your own version.

This echoes Simpson’s free-distribution ethos adapted for modern times. We sell a professional, lab-tested product for those who want convenience and quality assurance. We give away the recipe for those who want to DIY.

The Bentley Golden Paste Recipe (Our Original Open-Source Formula):

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 tsp freshly ground black pepper (for absorption)
• CBD oil (dosage per pet’s needs)

Instructions: Mix turmeric and water, heat into paste (7-10 min). Add coconut oil and pepper. Cool, store refrigerated up to 2 weeks. Mix with pet’s food. This is the formula that saved Bentley—published free years before our RSO formulas.

4. Evidence-Informed, Not Evidence-Overstating

Our GENERAL KNOWLEDGE section (see below) applies formal evidence hierarchy: human clinical data first, then systematic reviews, then institutional summaries, then preclinical literature. We distinguish what is well-supported from what is emerging from what is overstated.

We don’t exempt ourselves from these standards. Where we cite research for our products, we provide the source evaluation context—the same peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework.

As Colin said in 2019: “I’m not trying to sell people snake oil… people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Farm Bill Compliance: Legal Access for Shelby County

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC by dry weight. This is our foundation.

Our Sublingual Oil: 90mg delta-9 THC total in 30mL bottle = 3mg/mL—far below the 0.3% threshold. All cannabinoids are hemp-derived. This product is legal under federal law and in Indiana.

International Implications: Because our product meets Farm Bill standards, we can ship internationally to jurisdictions with compatible hemp laws. A cancer patient in Germany, a chronic pain sufferer in Australia, or a veteran in the UK can access the same formula you can order from Shelby County. Rick Simpson could never ship his oil anywhere—it was Schedule I everywhere. We’ve made his vision globally accessible, legally.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding local laws. We ship with full documentation, COAs, and receipts. International customers accept all customs and legal risk. Contact us: (832) 416-2816 or [email protected].

For Shelby County residents, this means you can legally purchase, possess, and use our raw THCa formula. If you choose to decarboxylate it at home, you’re making a personal choice about activation—the same choice Shelby County homebrewers make when they ferment their own beer. The product stays legal throughout.

Solvent-Free Production: Why It Matters for Your Health

Traditional RSO used naphtha or isopropyl alcohol—toxic, non-food-grade solvents. Modern extraction uses food-grade ethanol or supercritical CO₂ with validated testing.

Our Process: We don’t extract with solvents. We formulate using individual cannabinoid distillates and isolates combined in a controlled environment. No naphtha. No butane. No contamination risk.

Carrier: Organic MCT oil (medium-chain triglycerides)—food-grade, facilitates absorption, neutral taste. No tar-like consistency. No solvent-residual odor.

Testing: Third-party labs test for cannabinoid potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants. COAs available on request via our website.

For Shelby County residents concerned about product safety—especially those with compromised immune systems from cancer treatment—this matters. You deserve to know exactly what’s in your medicine.

Two Product Formats: Which Is Right for You?

We offer RSO in two formats because different Shelby County situations call for different tools.

RSO Sublingual Oil – $129.99

Specifications:

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg/mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper (0.1mL increments)

Pharmacokinetics:

• Onset: 15-45 minutes (sublingual absorption)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (bypasses first-pass liver metabolism)
• 40-60 doses per bottle

Best For: Sustained relief, precise dosing, daytime non-psychoactive use (raw), nighttime psychoactive use (decarbed).

RSO Vape Cartridge – $49.99

Specifications:

• 1-gram cartridge
• 900mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual (no separate delta-9 listed—auto-decarbs at vape temp)
• Live terpenes at 5%+
• 510-thread universal battery compatibility

Pharmacokinetics:

• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (varies by inhalation technique)
• Auto-decarboxylation at 400-450°F

Best For: Fast relief, acute breakthrough pain, panic attacks, nausea, portability.

When to Use Each Format

Use Case	Recommended Format	Why
Fast relief (acute pain, panic, nausea)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep maintenance)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability/discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated THCa + delta-8

For Shelby County residents who work at Rolls-Royce in Indianapolis or commute to Louisville, the vape offers discreet relief during a stressful day. For those managing chronic pain from farming injuries or factory work, the sublingual oil provides sustained support.

Competitive Comparison: How OilWell RSO Stacks Up

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Feature	TCUP Dispensary	OilWell
Cannabinoid profile	THC-only (~420mg per 0.5g syringe)	7 cannabinoids: CBD, CBG, delta-8, THCa, delta-9, CBN, CBC
CBG content	0mg	3,000mg
Patient-controlled potency	No—always psychoactive	Yes—raw THCa option
Access requirements	TCUP medical card + qualifying condition	Age 21+ only
Delivery	Must travel to dispensary	Ships to Shelby County
Legal framework	State medical program	Farm Bill compliant

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Feature	Lazarus Naturals (10mL, 1,000mg)	OilWell (30mL, 16,590mg)
Total cannabinoids	1,000mg	16,590mg
CBD content	~950mg	4,500mg
Delta-8 THC	0mg	6,000mg
THCa (convertible)	Minimal	1,500mg (~1,315mg delta-9 when decarbed)
Psychoactive option	No meaningful effect	Yes—via THCa activation
Price	$40-50	$129.99

OilWell RSO vs. Traditional Illegal RSO

Refer to the 11-dimension comparison table in the Rick Simpson section above. Key points for Shelby County:

• Safety: No toxic solvents vs. naphtha/isopropanol.
• Standardization: Lab-tested consistency vs. batch-to-batch variability.
• Potency Control: You choose psychoactive level vs. always high-THC.
• Legality: Farm Bill compliant vs. Schedule I.

Condition-Specific Usage Context for Shelby County

Critical Disclaimer: These contexts are informed by research cited in our GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved, and not a substitute for professional care. Always consult your healthcare provider—whether at IU Health, Franciscan, or your local Shelbyville clinic—before using cannabinoid products. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea & Appetite Support

For Shelby County cancer patients traveling to IU Health Simon Cancer Center or receiving treatment at Community Hospital South:

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment.
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset).
• Post-chemo: 0.5mL sublingual every 6 hours as needed.
• Sleep support: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN).

Evidence Context: Delta-8 THC antiemetic properties [9], delta-9 THC for nausea/vomiting [1][13], CBD for anxiety buffering [3].

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Shelby County residents dealing with pain from years of physical labor, manufacturing work, or farming:

• Daytime: 0.3-0.5mL raw sublingual—anti-inflammatory without impairment.
• Nighttime: 0.5-1.0mL decarbed sublingual—combines pain relief with CBN sleep support.
• Breakthrough pain: Vape as needed for rapid onset.

Evidence Context: CBD for pain [4], delta-9 THC for pain [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12].

Sleep Support

For Shelby County residents struggling with insomnia—whether from stress, pain, or shift work:

• Before bed: 1.0-2.0mL sublingual.
• At 2.0mL: Delivers 50mg CBN—the dosage studied in 2024 sleep literature.
• At 1.0mL: Delivers 25mg CBN—above the 20mg threshold associated with reduced sleep disturbance.

Evidence Context: CBN sleep studies [16][17], cannabis and sleep review [17].

Anxiety & Stress

For Shelby County residents managing PTSD (especially veterans), work stress, or caregiving pressures:

• Daytime functional relief: 0.3mL raw sublingual—CBD and CBG address anxiety pathways without impairment.
• Nighttime: 1.0mL sublingual—full profile including CBN for sleep architecture.

Evidence Context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage effects [20].

General Titration Principle for Shelby County

Start Low, Go Slow. We recommend beginning with 0.25-0.5mL sublingual and assessing effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and concurrent medications. For Shelby County residents who may be taking other prescriptions, this cautious approach is especially important.

Delivery to Shelby County: How to Get Your Order

Same-Day Delivery in Houston (Not Applicable to Shelby County)

We operate the only same-day RSO delivery system in Houston, with free delivery to the Texas Medical Center (world’s largest medical complex, 10M+ patient visits annually). While this doesn’t extend to Shelby County, it demonstrates our commitment to accessibility for patients who need immediate access.

Nationwide Shipping to Shelby County, Indiana

For Shelby County residents, we ship via:

• USPS Priority Mail: 2-3 business days to Shelbyville, Morristown, or anywhere in Shelby County.
• FedEx/UPS Ground: 3-5 business days.
• Discreet Packaging: No cannabis branding visible—plain box, discrete return address.
• Tracking: Provided for all orders.
• Temperature-Stable Packaging: Summer shipments protected from Indiana heat.
• Signature-Required Option: Available for security.

International Shipping

Our international service doesn’t directly affect Shelby County, but it’s worth noting: we’ve delivered to multiple continents. Our PANDEM1C SEO technology—with 14 million geopolitical locations and 300+ AI models—drives organic visibility globally. Rick Simpson couldn’t ship anywhere legally. We’ve made his vision borderless.

Ordering for Shelby County Residents

• Website: OilWell Cannabis RSO Guide
• Phone: (832) 416-2816
• Email: [email protected]
• Business Hours: Mon-Thu 10AM-7PM, Fri-Sat 10AM-10PM, Sun 10AM-4PM (Central Time)

For Shelby County: Orders placed before 2PM Central ship same day. Arrive in 2-3 business days via USPS Priority.

Our Product Formulas: Complete Transparency

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

Additional Specifications:

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Dropper: Graduated 0.1mL increments
• Price: $129.99

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Additional Specifications:

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Battery: 510-thread universal
• Price: $49.99

Terpene Profile (Both Products)

• Limonene: Citrus-bright, mood support
• Myrcene: Relaxation (preclinical evidence)
• Caryophyllene (β-caryophyllene): Pepper/spice, CB2 agonist [24]
• Pinene: Forest-fresh, clarity (exploratory evidence)
• Linalool: Floral/lavender, calm (exploratory evidence)
• Humulene: Earthy/woody, inflammation (preclinical)
• Terpinolene: Piney/fruity, complexity (preclinical)

GENERAL KNOWLEDGE: The Science Behind Our Claims

Research Method & Evidence Weighting

We prioritize: Human clinical evidence → Systematic reviews → Institutional summaries (NIH, NCCIH) → Preclinical literature. This matters because the evidence base is uneven.

CBD and Delta-9 THC: Strongest human literature.
Delta-8 THC, THCa, CBG, CBN, CBC, Terpenes: Depend more on reviews, animal studies, and preclinical work [1]-[29].

Institutional Baseline (NIH, NCCIH, FDA)

Strongest Established Evidence:

• Rare epilepsies (purified CBD) [1][2]
• Chemotherapy-related nausea/vomiting (THC-containing medicines) [1][13]
• HIV/AIDS appetite/weight loss [1]

Modest Evidence:

• Chronic pain [1][4][13]
• Multiple sclerosis symptoms [1]

Not Approved:

• FDA has not approved the cannabis plant itself for medical use [1]
• No cannabis plant product approved for cancer [1]

Safety Concerns (NIH/NCCIH):

• Impairment, motor vehicle crash risk [1]
• Cannabis use disorder [1][15]
• Pregnancy concerns [1]
• Contamination/labeling inaccuracy [1][10][11]
• Drug interactions (especially CBD) [1][6]
• THC-vape lung injury concerns [1]

Cannabinoid Evidence Profiles

CBD

Strongest Evidence: Seizure disorders (Epidiolex) [1][2]

Anxiety: 2024 systematic review of 316 participants across 8 studies showed significant anxiolytic signal but authors stressed limited clinical sample—more trials needed [3]

Pain: 2024 systematic review concluded promising but heterogeneous; trial quality limits confidence [4]

Sleep: 2023 insomnia review found literature methodologically weak, few objective assessments [5]

Safety: 2023 review found liver enzyme elevation and possible drug-induced liver injury risk, especially with concentrated oral products and polypharmacy [6]. Also: diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, drug-drug interactions [1]

Bottom Line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence limited to specific indications [1]-[6]

CBG

Evidence: Mostly review/preclinical; human evidence sparse [7][8]

Pharmacology: Biosynthetic precursor; interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling—mechanistically interesting but not clinically established [7]

Potential Areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily preclinical hypotheses [7][8]

Caution: Commercially sold while evidence base remains thin—claims often outrun science [7]

Bottom Line: Promising minor cannabinoid, limited clinical validation [7][8]

Delta-8 THC

Evidence: Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 [9]-[11]

Pharmacology: 2022 review concluded similar PK/PD to delta-9; partial CB1 agonist, less potent due to weaker affinity [9]

Public Health: 2023 scoping review found evidence base dominated by animal studies, chemistry, use reports, and safety concerns—few strong human trials [10]. Noted adverse consequences, regulatory/product-quality concerns [10]

Manufacturing: Commercial interest tied to stability and easier synthesis vs. naturally scarce plant levels—raises byproduct/testing questions [11]

Bottom Line: Psychoactive THC analogue with real activity, incomplete safety characterization, manufacturing-quality uncertainties [9]-[11]

THCa

Evidence: Important chemically, low direct human therapeutic evidence [12]

What It Is: Acidic precursor to THC; may represent large share of raw plant THC content. Decarboxylates to THC with heating/time [12]

Psychoactivity: THCa itself is not psychoactive, but distinction only holds if molecule stays acidic and isn’t decarboxylated [12]

Research: In vitro/rodent literature suggests anti-inflammatory (COX-2), immunomodulatory, neuroprotective, antineoplastic possibilities—not established human outcomes [12]

Bottom Line: Relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage [12]

Delta-9 THC

Evidence: Strongest human evidence among psychoactive cannabinoids, clearest adverse-effect burden [1][13]-[15]

Institutional Support: NCCIH identifies relevance to chemo nausea/vomiting, HIV/AIDS appetite, some MS/pain outcomes—many other uses uncertain [1]

Pain: 2022 systematic review of cannabis-based products found high-THC or THC:CBD products may provide short-term pain benefit but increased dizziness, sedation, nausea, discontinuation [13]

Pharmacokinetics: Inhaled: seconds-minutes onset, peaks 15-30 min, lasts few hours. Oral: later onset, later peak, longer duration—critical for benefit and overconsumption risk [14]

Mental Health Risk: 2025 systematic review of high-concentration THC found consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder; concerning signals for anxiety/depression in nontherapeutic settings [15]

Broader Safety: Anxiety/panic at high doses, tachycardia, hypotension, dependency, withdrawal, pregnancy concerns, pediatric exposure, vape lung injury [1][14][15]

Bottom Line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

Evidence: Weak human evidence; marketing ahead of data [12][16][17]

Marketing Claims: Sleep and sedation—reputation widespread but clinical support thin [16][17]

Sleep Research: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles—found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]

Broader Sleep Literature: 2024 updated review concluded cannabinoid sleep research doesn’t match real-world use scale; need for better-designed, adequately powered trials remains substantial [17]

Chemical Context: THC can degrade to CBN under certain conditions—explains discussion in aging/oxidized cannabis contexts [12]

Bottom Line: Cultural reputation stronger than current clinical evidence—clearest example in this field where marketing outpaces data [16][17]

CBC

Evidence: Emerging, intriguing, overwhelmingly preclinical/review-based [18][19]

Pharmacology: 2024 focused review argues distinct PK/PD and receptor behavior vs. better-known cannabinoids; highlights antinociceptive, antibacterial, anti-seizure as interesting targets [18]

Older Literature: Review of animal/in vitro work reports anti-inflammatory, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative relevance—not patient-facing evidence [19]

Safety Caveat: 2024 CBC review notes over-the-counter products sold despite little evidence establishing clinical efficacy or safety [18]

Bottom Line: Scientifically credible minor cannabinoid deserving more research—not validated clinical active [18][19]

Terpene Evidence Profiles

Important: Terpene claims need stricter interpretation than cannabinoids. Much literature from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

Evidence: Review/preclinical, useful safety literature [20]-[22]

Potential Activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—mostly nonhuman/non-cannabis literature [21]

Safety: Limonene oxidation products (hydroperoxides) are clinically relevant contact allergens—important in patch-testing literature [22]

Bottom Line: Biologically active, widely discussed, but cannabis-specific therapeutic claims should stay conservative [20]-[22]

Myrcene

Evidence: Mostly preclinical, very limited human evidence [20][23]

Research: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, possible mechanisms—but explicitly states human studies lacking [23]

Interpretation Caution: Often invoked as proven sedative explaining couch-lock—stronger claim than human evidence supports [20][23]

Bottom Line: Plausible bioactivity, but compound-specific claims about mood/pain/sedation ahead of definitive human proof [23]

Caryophyllene

Evidence: Among most mechanistically interesting—direct cannabinoid-system relevance—but mostly preclinical [24]

Why It Stands Out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual, especially relevant pharmacologically [24]

Research Themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective—human clinical confirmation limited [24]

Bottom Line: Strongest candidate for terpene with cannabinoid-system significance, but not clinically proven for commonly attributed outcomes [24]

Pinene

Evidence: Promising preclinical, weak human confirmation [20][25]

Brain-Health Framing: 2021 review on pinene and linalool found antioxidant, anti-inflammatory, neuroprotective signals justifying future study—but emphasized evidence mostly preclinical, well-designed clinical trials lacking [25]

Interpretation Caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain hypotheses, not settled facts [20][25]

Bottom Line: Deserves scientific attention, but strong cognition claims should be exploratory [25]

Linalool

Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]

Research: Repeatedly discussed for stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts—lacking robust human trials [25]

Additional Literature: Separate reviews discuss possible antidepressant mechanisms, neuropharmacologic relevance—translational, not definitive clinical story [26]

Safety: Oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]

Bottom Line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing over firm therapeutic promises [22][25][26]

Humulene

Evidence: Translationally interesting, early stage [20][27]

Scoping Review: 2024 review analyzed 340 articles—broad preclinical evidence for anti-inflammatory effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]

Interpretation Caution: Findings valuable for hypothesis generation, don’t establish consistent human efficacy across pain/inflammation/mood outcomes [27]

Bottom Line: More interesting terpene research target, but far from clinically settled [27]

Terpinolene

Evidence: Least clinically characterized in this file [20][28]

Systematic Review: 2021 review screened 2,449 records, included 57 studies—concluded terpinolene has range of reported biological effects but evidence base dominated by in silico, in vitro, animal studies—human trials scarce [28]

Bottom Line: Biologically interesting, but especially underdeveloped clinically [20][28]

Research Limits & Interpretation Caveats

1. Evidence Base is Highly Uneven: CBD and delta-9 THC support most detailed statements; others require caution [1]-[29].
2. Data Not Interchangeable: Whole-cannabis extract, purified molecule, semisynthetic, and terpene-only data are distinct. Common error: letting evidence from one category stand for another.
3. Minor Cannabinoids Are Commercially Interesting Because Underexplored: This also means claims often inflated.
4. Product Quality Matters as Much as Molecule Identity: Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent PK all affect real-world interpretation [1][10][11][14].
5. THCa Chemistry Changes With Storage/Heating: Storage and heating convert acidic cannabinoids to neutral forms like THC [12].

Common Overstatements to Avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
Accurate: Sleep evidence for CBN remains weak, no strong validated-trial base [16][17].

Overstatement: Myrcene is proven human sedative explaining couch-lock.
Accurate: Myrcene has plausible preclinical bioactivity, but direct human proof limited [20][23].

Overstatement: Terpenes have proven entourage effects in patients.
Accurate: Entourage hypotheses influential, but robust clinical proof limited and compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
Accurate: THCa itself isn’t THC, but heating/processing converts it to THC, changing exposure [12].

Overstatement: Delta-8 THC is safe because hemp-derived.
Accurate: Delta-8 is psychoactive, pharmacologically close to delta-9, entangled with manufacturing/testing concerns [9]-[11].

Practical Takeaways for Our Formulas

• Most Evidence-Developed Actives: CBD and delta-9 THC.
• Delta-8 THC: Not trivial or mild—psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9.
• THCa: Changes meaningfully with processing—interpret raw, gently-handled, and heated formats differently.
• CBG/CBN/CBC: Scientifically credible but clinically immature vs. CBD/THC.
• Terpenes: Relevant to aroma/flavor, possibly some bioactivity, but compound-specific human therapeutic claims should be careful and directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

Rick Simpson References

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

Conclusion: A Promise to Shelby County

OilWell Cannabis is more than a brand—we’re a promise. We promise to deliver the best, most thoughtfully formulated cannabis products available. We promise to educate honestly, without hype. We promise to respect your intelligence and your right to make informed decisions about your health.

From the day Bentley got up and brought his ball to play, our mission has been clear: create real solutions that alleviate pain and suffering, not just for pets but for people—for veterans in Shelbyville struggling with PTSD, for cancer patients in Morristown searching for relief, for chronic pain sufferers across Shelby County who’ve been failed by pharmaceuticals.

We don’t follow trends. We set them. And as we continue to grow, our focus remains on maintaining the integrity, creativity, and commitment that has defined us from day one.

For Shelby County residents ready to explore RSO: Visit our complete guide at OilWell Cannabis RSO Guide. Order online or call (832) 416-2816. We’ll get it to your doorstep in Shelby County, legally and discreetly, with all the documentation you need.

For those who can’t afford our products: The formulas are published here. Source the ingredients. Make your own. That’s what open-source means.

For those who want the best: We’ve done the research, perfected the formulation, and tested it rigorously. Our products are ready for you.

Shelby County, you’re not alone in this. We’re here to help you navigate your cannabinoid journey with honesty, science, and respect. Because everyone deserves access to medicine that works—and the information to use it wisely.